EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
Spleen Cytokines Against Inflammatory Bowel Disease
Over one hundred years ago at the University of Toronto Frederick Banting Charles Best and James Collip extracted protein insulin from the pancreas that saved the lives of millions of diabetics since then It is possible that the proteins extracted from the spleen can also help people with inflammatory bowel disease IBD
B2B Pharma Magazines: Sponsored Thought Leadership Strategies for Brand Authority
The pharmaceutical industry has never been short of innovation Every year brings breakthroughs in biologics advanced therapies AIdriven drug discovery manufacturing automation precision medicine and digital health
Pharmaceutical Business Strategy: Transformation, Regulation, Outsourcing and Growth
The pharmaceutical industry is standing at an unusual crossroads Patent cliffs are steeper regulators are tougher patients expect more transparency and payers are pushing back harder on price In this environment a strong Pharma Business Strategy is no longer a slide deck exercise for the boardroom its the difference between a company that scales globally and one that quietly fades into irrelevanc...
B2B Lead Generation Pharma: High-ROI Tactics for European Markets
The European pharmaceutical industry can be called one of the most complicated and highly regulated markets in the world In the global market where a centralized approval system under the oversight of the European Medicines Agency EMA is required to the reimbursement systems specific to each country in Germany France Italy Spain and the Nordics market entry and market growth needs the accuracy of...
How AI Could Improve R&D Productivity Across the European Pharma Sector
Few industries invest in the future as heavily as European pharma According to the regions pharmaceutical industry federation the sector invested an estimated billion in research and development in Europe in making it the most researchintensive industry on the continent Yet boards increasingly confront an uncomfortable asymmetry Spending keeps climbing while the outputs that matter most
Gene Therapy: Breakthrough Treatments for Rare Diseases
The idea of gene therapy is radically changing the sphere of medicine with the possibilities to cure the patients with the rare hereditary diseases These diseases which are usually brought about by the alteration of the sequence
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases
Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
B2B Pharma Magazines: Sponsored Thought Leadership Strategies for Brand Authority
Kate Williamson
Decision-makers in the pharmaceutical industry rarely respond to promotional messaging alone. They look for evidence, expertise, and credible perspectives that help solve complex business and scientif...
-
2
Pharmaceutical Business Strategy: Transformation, Regulation, Outsourcing and Growth
Kate Williamson
This article explores how modern pharma business strategy blends strategic management, transformation, and outsourcing to drive sustainable growth. It examines evolving operating models, regulatory-dr...
-
3
B2B Lead Generation Pharma: High-ROI Tactics for European Markets
Kate Williamson
The pharmaceutical industry in Europe is changing due to regulatory pressures, the acceleration of the digital industry, and value-based care models. In case of B2B pharma marketer, lead generation sh...
-
4
How AI Could Improve R&D Productivity Across the European Pharma Sector
Lakshmi
Europe’s pharmaceutical industry invested an estimated €55 billion in R&D in 2024, yet the region’s share of global commercial clinical trials has almost halved in a decade. This...
-
5
Gene Therapy: Breakthrough Treatments for Rare Diseases
Kate Williamson
As a novel healing technique, gene therapy targets core issues in hereditary diseases. This is another approach where damaged genes are altered or removed; this has a ray of hope in diseases like SCID...
press releases Read more...
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Biomea Fusion Inc a clinicalstage biopharmaceutical company today announced that it will report results from its Phase I GLP clinical study evaluating BMF an investigational nextgeneration oral smallmolecule GLP receptor agonist on Tuesday
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Bristol Myers Squibb announced positive topline results from the planned interim analysis of the ACTION trial NCT conducted by RayzeBio Inc a Bristol Myers Squibb company The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progressionfree surv...
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
Jupiter Neurosciences Inc NASDAQ JUNS a clinicalstage biopharmaceutical company developing investigational therapies for neurodegenerative diseases today announced that the first patient has been dosed
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
Telix Pharmaceuticals Limited today announces that the first patients in the United States US have been dosed with Pixclara floretyrosine F or FFET its FDAapproved amino acid positron emission
Events Read more...
12 - 13
Oct 2026Pharmaceutics 2026
Village Hotel Changi, Singapor...
12 - 13
Oct 20262nd International Conference on Drug Discovery
Village Hotel Changi, Singapor...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
LATEST NEWS Read more...
Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio
Catalent Inc the leading global contract development and manufacturing organization CDMO dedicated to helping people live better and healthier lives and Mantra a consumer health company developing singleserve over the counter OTC oral gel products for everyday relief
Amphista Therapeutics Announces First Patient Dosed in AMX-883 Phase 1 Clinical Trial for Acute Myeloid Leukemia
Amphista Therapeutics Limited a leader in the discovery and development of noncereblon VHL targeted protein degradation TPD medicines today announced dosing of the first patient in a Phase trial for its lead candidate AMX Initiated following authorization from the US Food and Drug Administration i...
Sensible Biotechnologies Secures $47 Million to Advance Cell-Based mRNA Platform
Sensible Biotechnologies has secured million in financing to advance and scale its platform for producing naturally modified messenger RNA mRNA medicines The funding includes a Series A round
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio and TychoBio have entered into a collaboration to generate fulllength RNA data for training artificial intelligence AI models designed to support RNA therapy development for rare diseases
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialise EXPAREL® in the European Union and UK
Pacira BioSciences has entered into a strategic agreement with Molteni Farmaceutici to expand access to EXPAREL bupivacaine liposome injectable suspension for postsurgical pain management across selected European markets
ORIC Pharmaceuticals and Cancer Research UK Partner to Advance CIP2A-Targeted Cancer Therapy
ORIC Pharmaceuticals has entered into an agreement with Cancer Research UK to advance ORIC a potential firstinclass therapy targeting Cancerous Inhibitor of PPA CIPA into clinical development



